4 edition of Prediction of response to cancer therapy found in the catalog.
Includes bibliographies and index.
|Statement||editor, Thomas C. Hall.|
|Series||Progress in clinical and biological research ;, v. 276|
|Contributions||Hall, Thomas C., 1921-, International Congress of Chemotherapy (15th : 1987 : Istanbul, Turkey)|
|LC Classifications||RC271.C5 P729 1988|
|The Physical Object|
|Pagination||xiii, 309 p. :|
|Number of Pages||309|
|LC Control Number||88009392|
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during by: The levels of six inflammation mediators were measured in a cohort of prostate cancer patients undergoing radical radiotherapy, and CCL2 levels were found to be significantly higher in patients experiencing grade 2 toxicity. There is a growing interest in developing noninvasive approaches to monitor cancer progression and response to treatment. by: 1.
Hofmann, D. et al. WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. Interventional Oncology: Principles and Practice of Image-Guided Cancer Therapy 2nd Edition. Chapters on image guidance and targeting, tumor ablation, embolotherapy, and response assessment have been updated to reflect major technological advances, and new material on microwave ablation and irreversible electroporation has been added. Price: $
As a result, TM and SSM analyses performed equally well in early prediction and evaluation of therapy response. Li et al. reported similar findings for early prediction of breast cancer response to NACT. Nonetheless, water exchange across tissue compartments is a real physiological by: Novel gene expression assay can predict not only prognosis in many cancer types but whether tumors will respond to specific types of DNA-damaging therapy, sparing patients from unhelpful treatments.
ombudsman plan, essays on the worldwide spread of an idea
Union list of periodicals in South Australian college libraries and allied institutions
NASTRAN theoretical manual
Berlin Borough Camden County, New Jersey in the Second World War 1941-1945.
Cast-in-place concrete countertops
Atlas Diag Thoracoscopy
Carroll County, Tn
The Precision Editing Workbook
Brown Leather Book Cover, Standard Paperback Size
The 2000 World Market Forecasts for Imported Sewing Machines, Furniture and Equipment
Real old-time Yankee apple cooking.
Get this from a library. Prediction of response in cancer therapy. [Thomas C Hall; National Cancer Institute (U.S.). Cancer Clinical Investigation Review Committee.; University of Rochester.;]. Book Notes | 1 September Prediction of Response in Cancer Therapy.
Thirty-five papers, with discussions, from a symposium held February under the sponsorship of the National Cancer Institute and the University of Rochester.
Consideration of cell-kinetic, hormonal, immunological, genetic, and histological factors bearing on. Book Notes | 1 September Prediction of Response in Cancer Therapy. Thirty-five papers, with discussions, from a symposium held February under the sponsorship of the National Cancer Institute and the University of Rochester.
Consideration of cell-kinetic, hormonal, immunological, genetic, and histological factors bearing on. Within the oncology space, radiomics has found applications as a means of diagnosis, a prognostic tool predicting response to therapy 35 across organ systems, including but not limited to brain, 36–39 head and neck, 40–42 breast, 43–50 lung, 42,51–53 prostate, 54–58 rectum, 59–64 and liver.
65–69 In the context of lung cancer Cited by: 6. Mortazavi-Jehanno et al. investigated the predictive value of metabolic response in patients with metastatic breast cancer after 8 weeks of endocrine therapy, demonstrating that progression-free survival is related to metabolic response.
These observations suggest that changes in tumor SUV after endocrine therapy may be associated with Cited by: 2. Prediction of Response in Cancer Immunotherapy DAINIUS CHARA CIEJUS 1,2, JOHN J.L.
JA COBS 3, VIT A PAŠUK ONIENĖ 4, NIJOLĖ KAZLAUSKAITĖ. Neoadjuvant therapy has become part of standard treatment in several types of cancer. Therapeutic effects are often assessed with imaging.
The main purpose of response assessment is to define. Get this from a library. Prediction of response to cancer therapy: proceedings of a symposium held at the XVth International Chemotherapy Congress, Istanbul, Turkey, July[Thomas C Hall;].
Purpose: To prospectively document changes in contrast agent kinetics in patients with primary breast cancer treated with systemic chemotherapy after one or two cycles and to determine whether kinetic measures can be used to predict final clinicopathologic response.
Materials and Methods: Institutional committees on clinical research and ethics approval and patient consent were by: The prediction of response to therapy is a relatively new field of oncogenomics. The strong heterogeneity of individual tumors in terms of clinically observed drug response is an important reason for the need for individualized, molecular guided therapy, but also for the difficulties in realizing this by: The authors of “Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma” include Steve Y.
Cho, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, and currently the University of Wisconsin School of.
Since the introduction of chemotherapy for cancer treatment in the early 20th century considerable efforts have been made to maximize drug efficiency and at the same time minimize side effects.
As there is a great interpatient variability in response to chemotherapy, the development of predictive biomarkers is an ambitious aim for the rapidly growing research area of personalized Cited by: In triple-negative breast cancer, therapeutic response to carboplatin and docetaxel is similar.
However, carboplatin therapy is superior to docetaxel in Cited by: 1. Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer Min Ying, 1 Yingjian He, 1 Meng Qi, 1 Bin Dong, 2 Aiping Lu, 2 Jinfeng Li, 1 Yuntao Xie, 1 Tianfeng Wang, 1 Benyao Lin, 1 and Tao Ouyang 1.
e Background: Neoadjuvant treatment for breast cancer (BC) is an important remedy if the tumors are responding adequately. Still, there is no biomarker guidance resulting in many patients receiving chemotherapy with no efficient antitumor effect.
We study a multigene mRNA-based technology for drug response prediction (DRP). DRP has been thoroughly validated in other settings, Author: Anna Sofie Kappel Buhl, Ib Jarle Christensen, Steen Knudsen, Peter Buhl Jensen.
Holmes, H.L. and Little, J.M.: Tissue culture microtest for predicting response of human cancer to chemotherapy. Lancet 2: – (). PubMed CrossRef Google ScholarCited by: Response Prediction in Cancer Treatment Involving p53 Adapted Cancer Therapy In further embodiments the patient is predicted to be a patient who will suffer negative consequences of a therapy interfering with the cell cycle if the whole p53 gene is present in native form and a patient who will suffer negative consequences of a therapy.
Purpose: Most hormone receptor (HR)+/HER2− breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those patients who are likely to benefit. Using the Prosigna assay, we first evaluated the technical performance of core needle biopsy (CNB) tissues.
We then determined whether Prosigna risk of relapse (ROR) score and. This book is organized into 4 sections, each looking at the question of outcome prediction in cancer from a different angle. The first section describes the clinical problem and some of the predicaments that clinicians face in dealing with cancer.
In precision oncology, two major strategies are being pursued for predicting clinically relevant tumour behaviours, such as treatment response and emergence of drug resistance: inference based on Author: Maurizio Fazio.
We attempted to identify potent marker genes using a new statistical analysis and developed a prediction system for individual response to platinum/paclitaxel combination chemotherapy in ovarian cancer patients based on the hypothesis that expression analysis of a set of the key drug sensitivity genes for platinum and paclitaxel could allow us to predict therapeutic response to the Cited by: pre- and posttherapy scans.
Cervical cancer spreads primarily through direct extension, although lymphatic and hematogenous spread can result in distant metastases. Traditionally, clinical examination and cross-projectional imaging have been used to stage cervical cancer but are accurate in File Size: KB.Latest cancer articles, treatment info, research news and more for oncologists and medical professionals.
Read featured content on cancer research, treatment regimens and clinical studies.